Company Profile

Founded in 2010, Avraham Pharmaceuticals is a privately held, emerging pharmaceutical company developing novel products for treatment and prevention of neurodegenerative disorders. Our lead product candidate, Ladostigil, was exclusively in-licensed from the Hebrew University and the Technion, and is in Phase 2 clinical studies for MCI. Ladostigil is a multifunctional compound that combines neuroprotective mechanisms: reducing oxidative stress and microglial activation, and inhibiting proinflamtory cytokines. Ladostigil provides a drug candidate that may have the potential to slow progression to Alzheimer’s Disease in patients diagnosed with MCI.

Avraham has raised $18 million, which it has used to conduct several clinical trials in patients with MCI and Alzheimer’s Disease, supporting the development of its lead product candidate. Key Shareholders in the company include Yissum , Pontifax , CBI, Technion (TRDF) and others.